NeoGenomics, Inc. (NEO)
NASDAQ: NEO · Real-Time Price · USD
5.16
+0.32 (6.61%)
At close: Aug 1, 2025, 4:00 PM
5.06
-0.10 (-1.94%)
After-hours: Aug 1, 2025, 7:31 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 7 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $12.14, which forecasts a 135.27% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $22.
Price Target: $12.14 (+135.27%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 2 | 2 | 3 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 11 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $10 → $8 | Hold | Maintains | $10 → $8 | +55.04% | Jul 30, 2025 |
| Needham | Needham | Strong Buy Maintains $8.5 → $8 | Strong Buy | Maintains | $8.5 → $8 | +55.04% | Jul 29, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $18 → $12 | Buy | Maintains | $18 → $12 | +132.56% | May 6, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $17 → $10 | Hold | Maintains | $17 → $10 | +93.80% | May 1, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $15 → $10 | Strong Buy | Maintains | $15 → $10 | +93.80% | Apr 30, 2025 |
Financial Forecast
Revenue This Year
751.93M
from 660.57M
Increased by 13.83%
Revenue Next Year
837.26M
from 751.93M
Increased by 11.35%
EPS This Year
0.16
from -0.62
EPS Next Year
0.30
from 0.16
Increased by 89.02%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 790.7M | 879.6M | 988.5M | ||
| Avg | 751.9M | 837.3M | 923.7M | ||
| Low | 716.9M | 798.1M | 869.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.7% | 17.0% | 18.1% | ||
| Avg | 13.8% | 11.3% | 10.3% | ||
| Low | 8.5% | 6.1% | 3.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.23 | 0.42 | 0.62 | ||
| Avg | 0.16 | 0.30 | 0.51 | ||
| Low | 0.11 | 0.19 | 0.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 161.9% | 104.4% | ||
| Avg | - | 89.0% | 68.2% | ||
| Low | - | 16.1% | 35.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.